<code id='68A05B5450'></code><style id='68A05B5450'></style>
    • <acronym id='68A05B5450'></acronym>
      <center id='68A05B5450'><center id='68A05B5450'><tfoot id='68A05B5450'></tfoot></center><abbr id='68A05B5450'><dir id='68A05B5450'><tfoot id='68A05B5450'></tfoot><noframes id='68A05B5450'>

    • <optgroup id='68A05B5450'><strike id='68A05B5450'><sup id='68A05B5450'></sup></strike><code id='68A05B5450'></code></optgroup>
        1. <b id='68A05B5450'><label id='68A05B5450'><select id='68A05B5450'><dt id='68A05B5450'><span id='68A05B5450'></span></dt></select></label></b><u id='68A05B5450'></u>
          <i id='68A05B5450'><strike id='68A05B5450'><tt id='68A05B5450'><pre id='68A05B5450'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:focus    Page View:9694
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          In 'major milestone,' FDA approves first cell therapy for solid tumors
          In 'major milestone,' FDA approves first cell therapy for solid tumors

          MetastaticmelanomacellsJulioC.Valencia,/NCICenterforCancerResearchNearlyfourdecadesafteritsfirstconc

          read more
          Wildfire smoke exposes gaps in outdoor worker protections
          Wildfire smoke exposes gaps in outdoor worker protections

          ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

          read more

          Elevance, SCAN deals highlight health insurer acquisition scrutiny

          AdobeAdealisneverreallydoneuntilit’sdone.OnTuesday,twodifferentproposedinsuranceplanacquisitionsondi